Table 2.
Correlation of overall and progression-free survival (Kaplan–Meier estimates, log-rank tests and Cox regression) according to SMAD4 expression status (expressed vs. lost) in the total study population, the gemcitabine-based, fluoropyrimidine-based and gemcitabine–fluoropyrimidine-based treatment subgroups.
| Chemotherapy Subgroup | SMAD4 | n | % | OS (Months) | p (Log-Rank) | HR | 95% CI | PFS (Months) | p (Log-Rank) | HR | 95% CI |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | expressed | 51 | 35.7 | 7.8 | 0.656 | 1088 | 0.751–1.576 | 5.8 | 0.038 | 1565 | 1.020–2.399 |
| lost | 92 | 64.3 | 8.5 | 7.0 | |||||||
| Gemcitabine | expressed | 35 | 35.4 | 8.3 | 0.722 | 1069 | 0.680–1.679 | 6.8 | 0.037 | 1790 | 1.028–3.116 |
| lost | 64 | 64.6 | 8.3 | 8.9 | |||||||
| Fluopyrimidine | expressed | 10 | 40.0 | 11.5 | 0.104 | 0.471 | 0.187–1.190 | 3.6 | 0.185 | 0.524 | 0.198–1.387 |
| lost | 15 | 60.0 | 7.2 | 6.7 | |||||||
| Gemcitabine + fluopyrimidine | expressed | 6 | 31.6 | 4.3 | 0.017 | 4277 | 1.185–15.431 | 2.5 | 0.018 | 3489 | 1.148–10.603 |
| lost | 13 | 68.4 | 12.5 | 6.2 |